BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23995264)

  • 1. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma.
    Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    Skeletal Radiol; 2013 Dec; 42(12):1673-81. PubMed ID: 23995264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.
    Zhang L; Chen L; Xie Q; Zhang Y; Cheng L; Li H; Wang J
    BMC Med Imaging; 2015 Mar; 15():7. PubMed ID: 25885599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
    Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
    Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
    Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients.
    Ozülker T; Küçüköz Uzun A; Ozülker F; Ozpaçac T
    Nucl Med Commun; 2010 Jun; 31(6):597-603. PubMed ID: 20224457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
    Lee JW; Lee SM; Lee HS; Kim YH; Bae WK
    Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
    Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.
    Min JW; Um SW; Yim JJ; Yoo CG; Han SK; Shim YS; Kim YW
    J Korean Med Sci; 2009 Apr; 24(2):275-80. PubMed ID: 19399270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
    Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
    Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
    Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
    Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
    Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
    Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET.
    Fujimoto R; Higashi T; Nakamoto Y; Hara T; Lyshchik A; Ishizu K; Kawashima H; Kawase S; Fujita T; Saga T; Togashi K
    Ann Nucl Med; 2006 Jul; 20(6):399-408. PubMed ID: 16922468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
    Iagaru A; Mittra E; Dick DW; Gambhir SS
    Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
    Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
    Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Bone Metastases between
    Wang D; Yang Y; Zeng Z; Ye J; Guo C; Huang S; Guo X; Xiao J
    Contrast Media Mol Imaging; 2022; 2022():5975338. PubMed ID: 35494210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
    Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
    Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.